This company is no longer active
InDex Pharmaceuticals Holding Beheer
Beheer criteriumcontroles 2/4
InDex Pharmaceuticals Holding's CEO is Jenny Sundqvist, appointed in Jan 2023, has a tenure of 1.42 years. total yearly compensation is SEK3.54M, comprised of 64% salary and 36% bonuses, including company stock and options. directly owns 0.023% of the company’s shares, worth SEK65.60K. The average tenure of the management team and the board of directors is 4.6 years and 8.4 years respectively.
Belangrijke informatie
Jenny Sundqvist
Algemeen directeur
SEK 3.5m
Totale compensatie
Percentage CEO-salaris | 64.0% |
Dienstverband CEO | 1.4yrs |
Eigendom CEO | 0.02% |
Management gemiddelde ambtstermijn | 4.6yrs |
Gemiddelde ambtstermijn bestuur | 8.4yrs |
Recente managementupdates
Recent updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -SEK 56m |
Dec 31 2023 | SEK 4m | SEK 2m | -SEK 95m |
Compensatie versus markt: Jenny's total compensation ($USD338.03K) is above average for companies of similar size in the Swedish market ($USD256.68K).
Compensatie versus inkomsten: Insufficient data to compare Jenny's compensation with company performance.
CEO
Jenny Sundqvist (53 yo)
1.4yrs
Tenure
SEK 3,543,000
Compensatie
Ms. Jenny Sundqvist serves as Chief Executive Officer of InDex Pharmaceuticals Holding AB (publ) since January 01, 2023. She served as Chief Commercial Officer of Isofol Medical AB (publ) from January 1, 2...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Chief Executive Officer | 1.4yrs | SEK 3.54m | 0.023% SEK 65.6k | |
Deputy CEO & Chief Financial Officer | 7.1yrs | SEK 2.80m | 0.073% SEK 209.8k | |
Chief Scientific Officer | 2.1yrs | geen gegevens | 0.0017% SEK 4.9k | |
Head of Regulatory Affairs | 11.4yrs | geen gegevens | geen gegevens |
4.6yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: INDEX's management team is considered experienced (4.6 years average tenure).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Independent Director | 13.4yrs | SEK 235.00k | 0.081% SEK 232.4k | |
Independent Director | 8.4yrs | SEK 235.00k | 0.077% SEK 219.5k | |
Director | less than a year | geen gegevens | geen gegevens | |
Member of Advisory Board - North America | no data | geen gegevens | geen gegevens | |
Member of Advisory Board - Europe | no data | geen gegevens | geen gegevens | |
Independent Chairman | 13.4yrs | SEK 500.00k | 0.14% SEK 406.6k | |
Member of Advisory Board - Europe | no data | geen gegevens | geen gegevens | |
Chairman of Advisory Board - Europe | 2yrs | geen gegevens | geen gegevens | |
Member of Advisory Board - Europe | no data | geen gegevens | geen gegevens | |
Member of Advisory Board - Europe | no data | geen gegevens | geen gegevens | |
Member of Advisory Board - Europe | no data | geen gegevens | geen gegevens | |
Member of Advisory Board - North America | no data | geen gegevens | geen gegevens |
8.4yrs
Gemiddelde duur
70yo
Gemiddelde leeftijd
Ervaren bestuur: INDEX's board of directors are considered experienced (8.4 years average tenure).